Komarom-Esztergom Varmegyei Szent Borbala Korhaz — Clinical Trial Site

57 Registered trials

24 Currently recruiting

Organisation

Komarom-Esztergom Varmegyei Szent Borbala Korhaz

Location

Tatabanya, Hungary

Identifier

ORG-100041445

Address

Dozsa Gyorgy Ut 77, 2800, Hungary

Departments

2102: Gasztroenterológiai Osztály
2106: Neurology and Stroke Dept
3304:Tüdőgyógyászati Osztály
Aneszteziológiai és Intenzív Terápiás Osztály
Department of Gastroenterology
Department of Haematology
Department Of Neurology and Stroke
Fül-Orr-Gégészeti Osztály
Gastroenterology
Gasztoenterológiai osztály
Gasztroenterológia
Gasztroenterologiai osztaly
Haematologiai Osztaly
Hematológiai osztály
N/A
Neurológia- és Stroke Osztály
Neurology
Onkologia osztaly
Onkológiai Osztály
Otolaringology
Pulmonology
Tüdőgyógyászat
Tüdőgyógyászati Onkológiai Gondozó
Tudogyogyaszati osztaly

Clinical trials at this site (57)

Search interface

A Study of Lebrikizumab (LY3650150) in Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CO… Recruiting

2023-508760-29-00 Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) 5 2024-10-21
A Study Evaluating the Overall Survival of Patients with Extensive Stage Small Cell Lung Cancer Receiving Trilaciclib or Placebo prior to To… Recruiting

2022-502357-34-00 Extensive Stage Small Cell Lung Cancer 5 2023-09-27
Study of Neoadjuvant and Adjuvant Treatment in Patients with Resectable Non-small Cell Lung Cancer Recruiting

2023-508852-21-00 Resectable, Early-stage (II to IIIB) Non-small Cell Lun 4 2022-06-10
Clinical trial to evaluate safety and effectiveness of APL-101 for the treatment of advanced MET expressing solid tumors, including Non-Smal… Recruiting

2024-514542-37-00 Select advanced solid tumors and Non-Small Cell Lung Ca 9 2020-08-13
A Phase 2 Open-Label Safety and Efficacy Study of PF-06835375 Ended

2023-509338-21-00 Primary immune thrombocytopenia 4 2025-05-28
A clinical study of MK-7240 for the treatment of Crohn’s disease (MK-7240-008) Ended

2023-508636-61-00 Crohn’s Disease 5 2024-10-24
A Phase 3 study of belrestotug plus dostarlimab compared with placebo plus pembrolizumab in previously untreated PD L1 high NSCLC Ended

2023-504753-12-00 Lung Cancer, Non-Small Cell 5 2024-10-01
A Phase 3 Study of DB-1303 vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer Ended

2023-507333-17-00 HER2-low, Hormone Receptor Positive, Metastatic Breast 5 2024-04-15
Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer (DeLLphi-304) Ended

2022-502669-14-00 Small cell lung cancer (SCLC) 5 2023-12-18
A Phase 3 Placebo-controlled Study of Milvexian after an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack Ended

2022-501176-26-00 Acute Ischemic Stroke and High-Risk Transient Ischemic 5 2023-08-04
PH2a, Platform Study of Novel Immunotherapy Combinations in Participants with Previously Untreated, Advanced/Metastatic NSCLC Ended

2023-505057-40-00 Lung Cancer, Non-Small Cell 4 2022-12-02
A clinical trial to compare the effectiveness and safety of giredestrant with a subcutaneous combination of pertuzumab and trastuzumab versu… Ended

2022-500014-26-00 Locally-Advanced unresectable or Metastatic breast canc 5 2022-06-24
An International, Randomized, Double-Blind, Phase III Study of Fuzuloparib Combined with Abiraterone Acetate and Prednisone (AA-P) versus Pl… Ended

2023-509396-16-00 Metastatic Castration-Resistant Prostate Cancer 5 2021-11-08
A Phase 3 Trial of Epcoritamab vs Investigator’s Choice Chemotherapy in R/R DLBCL Ended

2023-504830-23-00 B-cell Lymphoma 5 2020-12-16
A Phase 3 Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment … Ended

2023-506365-64-00 Deleterious Germline or Somatic Homologous Recombinatio 5 2020-10-16
A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn’s Disease (VIVID-2) Ended

2022-502841-91-00 Crohn’s Disease 5 2020-08-12
A phase III multi-center, randomized, open-label trial to evaluate efficacy and safety of ribociclib with endocrine therapy as adjuvant trea… Ended

2023-510357-42-00 hormone receptor (HR)-positive, HER2-negative, early br 5 2019-05-22
Extended Access of Momelotinib for Subjects with Myelofibrosis Ended

2023-508018-41-00 Primary Myelofibrosis (PMF), Post-polycythemia Vera or 4 2018-07-27
A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects with Crohn's Disease who Comple… Ended

2023-504951-29-00 Crohn's Disease 5 2017-07-27
A study to compare the effect of AVT16 and Entyvio® in subjects with moderate to severe active ulcerative colitis. Ended

2023-507705-34-00 Moderate to Severe Active Ulcerative Colitis 5 2025-08-29
A Study designed to evaluate the efficacy and safety of tiragolumab plus atezolizumab compared with placebo plus atezolizumab administered i… Ended

2023-506696-10-00 Non-Small Cell Lung Cancer 5 2024-06-18
A Study to Evaluate the Efficacy and Safety of Astegolimab in Patients with Chronic Obstructive Pulmonary Disease Ended

2022-502234-70-00 Chronic Obstructive Pulmonary Disease (COPD) 5 2023-07-14
Long-term Safety and Efficacy of Efavaleukin Alfa in Subjects With Moderately to Severely Active Ulcerative Colitis Ended

2023-506046-24-00 Ulcerative Colitis (UC) 4 2023-07-03
Efficacy, Safety, Tolerability Study of LYR-210 Depot in Chronic Sinusitis Ended

2023-506268-15-00 Chronic Rhinosinusitis (CRS) in Adults 5 2023-06-05